[Click eStock] "HLB, Momentum Concentrated This Year Including Clinical Results"

[Asia Economy Reporter Hyunseok Yoo] Hanyang Securities analyzed on the 8th that HL Biotech has multiple upcoming momentum events this year, including clinical trial result announcements. The investment opinion of Buy and the target price of 144,500 KRW were maintained.

Byungyong Oh, a researcher at Hanyang Securities, said, "The biggest event this year is the announcement of the Phase 2 clinical trial results for the autologous dendritic cell therapy 'ITI1000' being developed by the subsidiary 'Immunomic Therapeutics.'" He added, "Recently, domestic and international cell therapy companies have announced clinical results with significant efficacy, leading to a sharp rise in their stock prices." He further stated, "'ITI1000' is also regarded as a promising cell therapy candidate with considerable potential."

Researcher Oh emphasized, "The Phase 2 clinical trial results of Lenvatinib for cholangiocarcinoma are also scheduled to be announced in the first half of the year," adding, "Since cholangiocarcinoma is a rare cancer with no established standard treatment, excellent results could lead to rapid commercialization."

The clinical results of the main pipeline are also highly anticipated. He explained, "The global Phase 3 trial for HL Biotech's main pipeline, 'Lenvatinib + Camrelizumab' for liver cancer, is nearing completion," and "The topline results of the global Phase 3 trial are expected around the end of this year, which is a big event."

He said, "Last year, the NDA for Lenvatinib in gastric cancer was continuously delayed due to COVID-19 issues, and there were no major events such as clinical result announcements or technology exports," adding, "This year, with the clinical results being announced, a positive stock price trend is expected going forward."

This content was produced with the assistance of AI translation services.